These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 21714538)

  • 1. Discovery of a tetrahydroisoquinoline-based hydroxamic acid derivative (ZYJ-34c) as histone deacetylase inhibitor with potent oral antitumor activities.
    Zhang Y; Fang H; Feng J; Jia Y; Wang X; Xu W
    J Med Chem; 2011 Aug; 54(15):5532-9. PubMed ID: 21714538
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of tetrahydroisoquinoline-based hydroxamic acid derivatives: potent histone deacetylase inhibitors with marked in vitro and in vivo antitumor activities.
    Zhang Y; Feng J; Jia Y; Wang X; Zhang L; Liu C; Fang H; Xu W
    J Med Chem; 2011 Apr; 54(8):2823-38. PubMed ID: 21476600
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Superior activity of a new histone deacetylase inhibitor (ZYJ-34c) in inhibiting growth of human leukemia cells by inducing p21WAF1 expression and cell cycle arrest.
    Yang H; Xu W; Li Y; Lan P; Zhang J; Zhang Y; Zhang C
    Anticancer Drugs; 2014 Aug; 25(7):767-77. PubMed ID: 24686006
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design and synthesis of a tetrahydroisoquinoline-based hydroxamate derivative (ZYJ-34v), an oral active histone deacetylase inhibitor with potent antitumor activity.
    Zhang Y; Liu C; Chou CJ; Wang X; Jia Y; Xu W
    Chem Biol Drug Des; 2013 Aug; 82(2):125-30. PubMed ID: 23581848
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potential anti-cancer activity of N-hydroxy-7-(2-naphthylthio) heptanomide (HNHA), a histone deacetylase inhibitor, against breast cancer both in vitro and in vivo.
    Park KC; Kim SW; Park JH; Song EH; Yang JW; Chung HJ; Jung HJ; Suh JS; Kwon HJ; Choi SH
    Cancer Sci; 2011 Feb; 102(2):343-50. PubMed ID: 21159061
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances taxol-induced cell death in breast cancer.
    Shi YK; Li ZH; Han XQ; Yi JH; Wang ZH; Hou JL; Feng CR; Fang QH; Wang HH; Zhang PF; Wang FS; Shen J; Wang P
    Cancer Chemother Pharmacol; 2010 Nov; 66(6):1131-40. PubMed ID: 20838997
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumor effects of a novel histone deacetylase inhibitor NK-HDAC-1 on breast cancer.
    Li ZH; Zhang XB; Han XQ; Feng CR; Wang FS; Wang PG; Shen J; Shi YK
    Oncol Rep; 2013 Jul; 30(1):499-505. PubMed ID: 23624828
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of a series of substituted 2-piperazinyl-5-pyrimidylhydroxamic acids as potent histone deacetylase inhibitors.
    Angibaud P; Van Emelen K; Decrane L; van Brandt S; Ten Holte P; Pilatte I; Roux B; Poncelet V; Speybrouck D; Queguiner L; Gaurrand S; Mariën A; Floren W; Janssen L; Verdonck M; van Dun J; van Gompel J; Gilissen R; Mackie C; Du Jardin M; Peeters J; Noppe M; Van Hijfte L; Freyne E; Page M; Janicot M; Arts J
    Bioorg Med Chem Lett; 2010 Jan; 20(1):294-8. PubMed ID: 19906529
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced pharmacodynamic and antitumor properties of a histone deacetylase inhibitor encapsulated in liposomes or ErbB2-targeted immunoliposomes.
    Drummond DC; Marx C; Guo Z; Scott G; Noble C; Wang D; Pallavicini M; Kirpotin DB; Benz CC
    Clin Cancer Res; 2005 May; 11(9):3392-401. PubMed ID: 15867240
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antitumor activity of suberoylanilide hydroxamic acid against thyroid cancer cell lines in vitro and in vivo.
    Luong QT; O'Kelly J; Braunstein GD; Hershman JM; Koeffler HP
    Clin Cancer Res; 2006 Sep; 12(18):5570-7. PubMed ID: 17000694
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of polyploidy by histone deacetylase inhibitor: a pathway for antitumor effects.
    Xu WS; Perez G; Ngo L; Gui CY; Marks PA
    Cancer Res; 2005 Sep; 65(17):7832-9. PubMed ID: 16140952
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxamates.
    Suzuki T; Nagano Y; Kouketsu A; Matsuura A; Maruyama S; Kurotaki M; Nakagawa H; Miyata N
    J Med Chem; 2005 Feb; 48(4):1019-32. PubMed ID: 15715470
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trichostatin A is a histone deacetylase inhibitor with potent antitumor activity against breast cancer in vivo.
    Vigushin DM; Ali S; Pace PE; Mirsaidi N; Ito K; Adcock I; Coombes RC
    Clin Cancer Res; 2001 Apr; 7(4):971-6. PubMed ID: 11309348
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The histone deacetylase inhibitor PXD101 synergises with 5-fluorouracil to inhibit colon cancer cell growth in vitro and in vivo.
    Tumber A; Collins LS; Petersen KD; Thougaard A; Christiansen SJ; Dejligbjerg M; Jensen PB; Sehested M; Ritchie JW
    Cancer Chemother Pharmacol; 2007 Jul; 60(2):275-83. PubMed ID: 17124594
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyclic hydroxamic-acid-containing peptide 31, a potent synthetic histone deacetylase inhibitor with antitumor activity.
    Komatsu Y; Tomizaki KY; Tsukamoto M; Kato T; Nishino N; Sato S; Yamori T; Tsuruo T; Furumai R; Yoshida M; Horinouchi S; Hayashi H
    Cancer Res; 2001 Jun; 61(11):4459-66. PubMed ID: 11389076
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gene expression-signature of belinostat in cell lines is specific for histone deacetylase inhibitor treatment, with a corresponding signature in xenografts.
    Monks A; Hose CD; Pezzoli P; Kondapaka S; Vansant G; Petersen KD; Sehested M; Monforte J; Shoemaker RH
    Anticancer Drugs; 2009 Sep; 20(8):682-92. PubMed ID: 19606018
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery, synthesis, and pharmacological evaluation of spiropiperidine hydroxamic acid based derivatives as structurally novel histone deacetylase (HDAC) inhibitors.
    Varasi M; Thaler F; Abate A; Bigogno C; Boggio R; Carenzi G; Cataudella T; Dal Zuffo R; Fulco MC; Rozio MG; Mai A; Dondio G; Minucci S; Mercurio C
    J Med Chem; 2011 Apr; 54(8):3051-64. PubMed ID: 21417419
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acylurea connected straight chain hydroxamates as novel histone deacetylase inhibitors: Synthesis, SAR, and in vivo antitumor activity.
    Wang H; Lim ZY; Zhou Y; Ng M; Lu T; Lee K; Sangthongpitag K; Goh KC; Wang X; Wu X; Khng HH; Goh SK; Ong WC; Bonday Z; Sun ET
    Bioorg Med Chem Lett; 2010 Jun; 20(11):3314-21. PubMed ID: 20451378
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytotoxic effects of Jay Amin hydroxamic acid (JAHA), a ferrocene-based class I histone deacetylase inhibitor, on triple-negative MDA-MB231 breast cancer cells.
    Librizzi M; Longo A; Chiarelli R; Amin J; Spencer J; Luparello C
    Chem Res Toxicol; 2012 Nov; 25(11):2608-16. PubMed ID: 23094795
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and evaluation of aliphatic-chain hydroxamates capped with osthole derivatives as histone deacetylase inhibitors.
    Huang WJ; Chen CC; Chao SW; Yu CC; Yang CY; Guh JH; Lin YC; Kuo CI; Yang P; Chang CI
    Eur J Med Chem; 2011 Sep; 46(9):4042-9. PubMed ID: 21712146
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.